FDA Novel Drug Approvals 2022 — Nearly 60% Small Molecules
January 18, 2023
The Food and Drug Administration (FDA) in the US approved 37 new drugs in 2022, considerably lower than the 50 approvals in 2021, yet still higher than the historic average of 34 approvals per year observed since 1993.
21 of the 37 drugs approved were small molecules, representing 57% of the total (compared to 28 out of 50 in 2021, 56%) showing the continued relevance, impact, and value of this class of drugs.
Cancer drugs dominated with 10 new oncology drugs. New drugs to treat diabetes, obesity, psoriasis, and an mRNA-based COVID-19 vaccine were particularly noteworthy for their ‘new target space, new clinical opportunities and untapped commercial potential.’
Availability in the Cambridge Structural Database
Drug (Brand Name) - Futibatinib (Lytgobi)
Futibatinib is an FGFR kinase inhibitor used to treat FGFR2-aberrant intrahepatic cholangiocarcinoma. CSD refcode: XISCUA.
Vonoprazan; Amoxicillin; Clarithromycin (Voquezna Triple Pak)
Voquezna combines a potassium-competitive acid blocker, a penicillin class antibacterial, and a macrolide antimicrobial. It is used to treat Helicobacter pylori infection.
Ganaxolone is a GABAA receptor positive allosteric modulator used to treat seizures associated with childhood disintegrative disorder (CDD), also known as Heller's syndrome and disintegrative psychosis. CSD refcode: RIGSOP.
Sodium Phenylbutyrate; Taurursodiol (Relyvrio)
Strong Vote for the Reliability of Computational Methods
Owing to animal testing being no longer required by the FDA before human drug trials can begin (legislation signed by President Joe Biden in late December 2022 - read the article in Science here), the reliability of computational methods drawing on quality, validated data sets like the CSD will increasingly become a powerful step in drug discovery. Combined with the seemingly unstoppable rise in AI, will the number of small molecule drug approvals increase over the coming years? Watch this space.
Learn more about the CSD — the most comprehensive repository of validated and curated small-molecule organic and metal-organic crystal structures.
Learn more about the software provided by the CCDC to get the most out of the data in the CSD.
Drug Development (30)
Drug Discovery (44)
Pharmaceutical Discovery (26)